Philip P. Boudreau
Known title: EVP AND CFOCIK: 0001805099
Philip P. Boudreau's purchase track record
Philip P. Boudreau has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/23/2026 | ABT | $201K | +9.7% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ABT | ▼ Sell | Tax Withholding | 388 | $43K | 9/1/2026 | View on chart |
| ABT | ▲ Buy | Open Market | 2,200 | $201K | 4/23/2026 | View on chart |
| ABT | ▼ Sell | Other | 8,909 | $820K | 4/23/2026 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 7,441 | $865K | 2/27/2026 | View on chart |
| ABT | ▲ Buy | Grant | 27,997 | $0 | 2/24/2026 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 387 | $51K | 9/1/2025 | View on chart |
| ABT | ▼ Sell | Open Market | 5,550 | $747K | 8/8/2025 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 4,908 | $667K | 2/28/2025 | View on chart |
| ABT | ▲ Buy | Grant | 22,495 | $0 | 2/25/2025 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 387 | $44K | 9/1/2024 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 1,738 | $209K | 2/29/2024 | View on chart |
| ABT | ▲ Buy | Grant | 23,024 | $0 | 2/21/2024 | View on chart |
| ABT | ▲ Buy | Grant | 2,620 | $0 | 9/1/2023 | View on chart |
| ABT | ▼ Sell | Open Market | 8,000 | $848K | 6/16/2023 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 1,477 | $147K | 2/28/2023 | View on chart |
| ABT | ▲ Buy | Grant | 4,855 | $0 | 2/17/2023 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 1,192 | $146K | 2/28/2022 | View on chart |
| ABT | ▼ Sell | Tax Withholding | 966 | $113K | 2/22/2022 | View on chart |
| ABT | ▲ Buy | Grant | 5,351 | $0 | 2/18/2022 | View on chart |
| ABT | ▼ Sell | Open Market | 8,000 | $1.0M | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Abbott Labs launches Ensure Max Protein as earnings preview approaches
Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.
Abbott Labs launches Ensure Max Protein as earnings preview approaches. Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.